Drug intelligence / Profile preview

DKM420

Development stage: Unknown
Lead developer: Dongkook Pharmaceutical
Modality: Small Molecules
Administration: Intraarticular

Overview

DKM420 is an investigational small molecule drug developed by Dongkook Pharmaceutical for the treatment of osteoarthritis, specifically osteoarthritis of the knee. It has been studied as an intra-articular injectable device in randomized, double-blind, active-controlled, pivotal clinical trials to assess efficacy and safety compared to existing treatments. The mechanism of action and precise molecular target of DKM420 have not been disclosed in publicly available sources, but it is classified as a treatment in the musculoskeletal therapeutic area, specifically for osteoarthritis of the knee[1][3][5][6][8].

Beyond the preview

Go deeper on DKM420.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DKM420.

Explore the full profile